Calcineurin inhibitors: A novel approach to canine atopic dermatitis

Journal of the American Animal Hospital Association

Volumn 41, Issue 2, 2005, Pages 92-97

  Marsella, Rosanna ^a  

^a University of Florida College of Veterinary Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ATOPICA; CALCINEURIN INHIBITOR; CYCLOPHILIN; CYCLOSPORIN; CYCLOSPORIN A; GAMMA INTERFERON; GLUCOCORTICOID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN E; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; KETOCONAZOLE; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE; TACROLIMUS; TRIAMCINOLONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ATOPIC DERMATITIS; DOG DISEASE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL DISEASE; HUMAN; IMMUNOGLOBULIN PRODUCTION; INFECTION; LONG TERM CARE; LYMPHOMA; NONHUMAN; PRURITUS; REVIEW; SKIN BURNING SENSATION; SKIN INFECTION; VETERINARY MEDICINE;

CANIS FAMILIARIS;

EID: 30944434518     PISSN: 15473317     EISSN: 15473317     Source Type: Journal    
DOI: 10.5326/0410092     Document Type: Review

References (68)

1. Groisser DS, Griffith CE, Ellis CN, et al. A review and update of the clinical uses of cyclosporine in dermatology. Dermatologic Clinics 1991;9:804-817.
2. Grossman RM, Chevret S, Abi-Rached J, et al. Long term safety of cyclosporine in the treatment of psoriasis. Arch Dermatol 1996; 23:1265-1275.
3. Gaig P, Aljotas J, Lopez A, et al. Cyclosporin A in atopic dermatitis. Allergologia et Immunopathologia 1993;21:169-172.
4. Sowden JM, Berth-Jones J, Ross JS, et al. Double-blind, controlled, cross-over study of cyclosporine in adults with severe refractory atopic dermatitis. Lancet 1991;338:137-140.
5. Lee SS, Tan AW, Giam YC. Cyclosporin in the treatment of severe atopic dermatitis: a retrospective study. Ann Acad Med Singapore 2004;33:311-333.
6. Coroas AS, de Oliveira JG, Magina S, et al. Cyclosporine enhances salt sensitivity of body water composition as assessed by impedance among psoriatic patients with normal renal function. J Ren Nutr 2004;14:226-232.
7. van Joost T, Heule F, Korstanje M, et al. Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study. Br J Dermatol 1994;130:634-640.
8. Rezzani R. Cyclosporine A and adverse effects on organs: histochemical studies. Prog Histochem Cytochem 2004;39:85-128.
9. De Rie MA, Mainardi MHM, Dos J. Lack of efficacy of topical cyclosporine A in atopic and allergic contact dermatitis. Acta Dermato-Venereologica 1991;71:452-454.
10. Hermann RC, Taylor RS, Ellis CN, et al. Topical cyclosporine for psoriasis: in vitro skin penetration and clinical study. Skin Pharmacol 1988;1:246-249.
11. Nuttall TJ, Knight PA, McAleese SM, et al. T-helper 1, T-helper 2 and immunosuppressive cytokines in canine atopic dermatitis. Vet Immunol Immunopathol 2002;87:379-384.
12. Hill PB, Olivry T. The ACVD task force on canine atopic dermatitis (V): biology and role of inflammatory cells in cutaneous allergic reactions. Vet Immunol Immunopathol 2001;81:187-198.
13. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporine A and FK-506. Immunology Today 1992;12:136-142.
14. Taylor AM, Galli SJ, Coleman JW. Dexamethasone or cyclosporin A inhibits stem cell factor-dependent secretory responses of rat peritoneal mast cells in vitro. Immunopharmacology 1996;34:63-70.
15. Stellato C, Depaulis A, Ciccarelli A, et al. Anti-inflammatory effect of cyclosporin-A on human skin mast cells. J Invest Dermatol 1992;98:800-804.
16. Garcia G, Ferrer L, De Mora F, et al. Inhibition of histamine release from dispersed canine skin mast cells by cyclosporin-A, rolipram and salbutamol, but not by dexamethasone or sodium cromoglycate. Vet Dermatol 1998;9:81-86.
17. Caproni M, Dagata A, Cappelli G, et al. Modulation of serum eosinophil cationic protein levels by cyclosporin in severe atopic dermatitis. Br J Dermatol 1996;135:336-337.
18. Meng Q, Ying S, Corrigan CJ, et al. Effects of rapamycin, cyclosporin A, and dexamethasone on interleukin 5-induced eosinophil degranulation and prolonged survival. Allergy 1997;52:1095-1101.
19. Hess AD. Mechanisms of action of cyclosporine: considerations for the treatment of autoimmune diseases. Clin Immunol Immunopathol 1993;68:220-228.
20. Rostaing L, Puyoo O, Tkaczuk J, et al. Differences in type 1 and type 2 intracytoplasmic cytokines, detected by flow cytometry, according to immunosuppression (cyclosporine A vs. tacrolimus) in stable renal allograft recipients. Clin Transplant 1999;13:400-409.
21. Teunissen MB, De Jager MH, Kapsenberg ML, et al. Inhibitory effect of cyclosporin A on antigen and alloantigen presenting capacity of human epidermal Langerhans' cells. Br J Dermatol 1991;125:309-316.
22. Thomson AW. The effects of cyclosporin A on non-T cell components of the immune system. J Autoimmun 1992;5(Suppl A):167-176.
23. Cockburn ITR, Krupp P. The risk of neoplasm in patients treated with cyclosporine A. J Autoimmun 1989;2:723-731.
24. Penn I, Branson ME. Cancers after cyclosporine therapy. Transplant Proc 1988;20(suppl 3):885-892.
25. Won YH, Sander DN, McKenzie RC. Cyclosporin A inhibits keratinocyte cytokine gene expression. Br J Dermatol 1994;130:312-319.
26. Olivry T, Mueller RS, International Task Force on Canine Atopic Dermatitis. Evidence-based veterinary dermatology: a systematic review of the pharmacotherapy of canine atopic dermatitis. Vet Dermatol 2003;14:121-146.
27. Fontaine J, Olivry T. Treatment of canine atopic dermatitis with cyclosporine: a pilot clinical study. Vet Rec 2001;148:662-663.
28. Olivry T, Rivierre C, Jackson HA, et al. Cyclosporine decreases skin lesions and pruritus in dogs with atopic dermatitis: a blinded randomized prednisolone-controlled trial. Vet Dermatol 2002;13:77-87.
29. Steffan J, Alexander D, Brovedani F, et al. Comparison of cyclosporine A with methylprednisolone for treatment of canine atopic dermatitis: a parallel, blinded, randomized controlled trial. Vet Dermatol 2003;14:11-22.
30. Olivry T, Steffan J, Fisch RD, et al., and the European Veterinary Dermatology Cyclosporine Group. Randomized controlled trial of the efficacy of cyclosporine in the treatment of atopic dermatitis in dogs. J Am Vet Med Assoc 2002;221:370-377.
31. Steffan J, Horn J, Gruet P, et al. Remission of the clinical signs of atopic dermatitis in dogs after cessation of treatment with cyclosporin A or methylprednisolone. Vet Rec 2004;154:681-684.
32. Rosenkrantz W. Immunomodulating drugs in dermatology. In: Kirk RW, ed. Current Veterinary Therapy X. Small Animal Practice. Philadelphia: WB Saunders, 1989:570-577.
33. Ryffel B, Donatsch P, Madörin M, et al. Toxicological evaluations of cyclosporin A. Arch Toxicol 1983;53:107-141.
34. Opelz G, Henderson R. Incidence of non-Hodgkin's lymphoma in kidney and heart transplant recipients. Lancet 1993;342:1514-1516.
35. McGregor JM, Yu CC, Lu QL, et al. Post-transplant cutaneous lymphoma. J Am Acad Dermatol 1993;29:549-554.
36. Ryffel B. The carcinogenicity of ciclosporin. Toxicology 1992;73:1-22.
37. Blackwood L, German AJ, Stell AJ, et al. Multicentric lymphoma in a dog after cyclosporine therapy. J Small Anim Pract 2004;45:259-262.
38. Robson D. Review of the pharmacokinetics, interactions and adverse reactions of cyclosporine in people, dogs and cats. Vet Rec 2003;152:739-748.
39. Kuroha M, Kuze Y, Shimoda M, et al. In vitro characterization of the inhibitory effects of ketoconazole on metabolic activities of cytochrome P-450 in canine hepatic microsomes. Am J Vet Res 2002;63:900-905.
40. Daigle JC. More economical use of cyclosporine through combination drug therapy. J Am Anim Hosp Assoc 2002;38:205-208.
41. Myre SA, Schoeder TJ, Grund VR, et al. Critical ketoconazole dosage range for ciclosporin clearance inhibition in the dog. Pharmacology 1991;43:233-241.
42. Dahlinger J, Gregory C, Bea J. Effect of ketoconazole on cyclosporine dose in healthy dogs. Vet Surg 1998;27:64-68.
43. Steffan J, Strehlau G, Maurer M, et al. Cyclosporin A pharmacokinetics and efficacy in the treatment of atopic dermatitis in dogs. J Vet Pharmacol Ther 2004;27:231-238.
44. Guaguere E, Steffan J, Olivry T. Cyclosporin A: a new drug in the field of canine dermatology. Vet Dermatol 2004;15:1-74.
45. Robson DC, Burton GG. Cyclosporin: applications in small animal dermatology. Vet Dermatol 2003;14:1-9.
46. Lazarous MC, Kerdel FA. Topical tacrolimus protopic. Drugs of today. Barcelona: Spain, 2002;38:7-15.
47. Rustin M. Tacrolimus ointment for the management of atopic dermatitis. Hosp Med 2003;64:214-217.
48. Gewirtz AT, Sitaraman SV. Tacrolimus fujisawa. Curr Opin Investig Drugs 2002;3:1307-1311.
49. Sakuma S, Higashi Y, Sato N, et al. Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system. (Comparison with steroids). Int Immunopharmacol 2001;1:1219-1226.
50. de Paulis A, Stellato C, Cirillo R, et al. Anti-inflammatory effect of FK-506 on human skin mast cells. J Investig Dermatol. 1992;99:723-728.
51. Thomson AW, Nalesnik M, Abu-Elmagd K, et al. The influence of FK-506 on T lymphocytes, Langerhans' cells, and the expression of cytokine receptors and adhesion molecules in psoriatic skin: a preliminary study. Transplant Proc 1991;23:3330-3331.
52. Wollenberg A, Sharma S, von Bubnoff D, et al. Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. J Allergy Clin Immunol 2001;107:519-525.
53. Trautmann A, Akdis M, Schmid-Grendelmeier P, et al. Targeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitis. J Allergy Clin Immunol 2001;108:839-846.
54. Trautmann A, Akdis M, Klunker S, et al. Role of apoptosis in atopic dermatitis. Int Arch Allergy Immunol 2001;24:230-232.
55. Allen BR. Tacrolimus ointment: its place in the therapy of atopic dermatitis. J Allergy Clin Immunol 2002;109:401-403.
56. Rustin M. Tacrolimus ointment for the management of atopic dermatitis. Hosp Med 2003;64:214-217.
57. Marsella R, Nicklin CF. Double blinded-placebo controlled, crossover study to evaluate the efficacy and safety of 0.3% topical tacrolimus in canine atopic dermatitis. Vet Dermatol 2002;13:203-210.
58. Marsella R, Nicklin CF, Saglio S, et al. Investigation on the clinical efficacy and safety of 0.1% tacrolimus ointment (Protopic®) in canine atopic dermatitis: a randomized, double-blinded, placebo-controlled, crossover study. Vet Dermatol 2004;15:294-303.
59. Deboer DJ, Schafer JH, Salsbury CS, et al. Multiple-center study of reduced-concentration triamcinolone topical solution for the treatment of dogs with known or suspected allergic pruritus. Am J Vet Res 2002;63:408-413.
60. Rico MJ, Lawrence I. Tacrolimus ointment for the treatment of atopic dermatitis: clinical and pharmacologic effects. Allergy Asthma Proc 2002;23:191-197.
61. Gupta AK, Adamiak A, Chow M. Tacrolimus: a review of its use for the management of dermatoses. J Eur Acad Dermatol Venereol 2002;16:100-114.
62. Fleischer AB Jr, Ling M, Eichenfield L. Tacrolimus ointment study group: tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. J Am Acad Dermatol 2002;47:562-570.
63. Pournaras CC, Lübbe J, Saurat JH. Staphylococcal colonization in atopic dermatitis treatment with topical tacrolimus (FK506). J Investig Dermatol 2001;116:480-481.
64. Nagai H, Hiyama H, Matsuo A, et al. FK-506 and cyclosporin A potentiate the IgE antibody production by contact sensitization with hapten in mice. J Pharmacol Exp Ther 1997;283:321-327.
65. Kawamura N, Furuta H, Tame A. Extremely high serum level of IgE during immunosuppressive therapy: paradoxical effect of cyclosporine A and tacrolimus. Int Arch Allergy Inummol 1997;112:422-444.
66. Wheeler DJ, Robins A, Pritchard DI, et al. Potentiation of in vitro synthesis of human IgE by cyclosporin A (CsA). Clin Exp Immunol 1995;102:85-90.
67. Clarke K, McCall C, Steffan J. The effects of cyclosporine A and oral prednisolone on flea allergen specific serum IgE and intradermal tests in experimentally sensitized laboratory beagles. Proceedings, 8th European Soc/European Coll Vet Dermatol, Nice, France, 2002:223.
68. Marsella R, Nicklin CF, Saglio S, et al. Investigation on the effects of topical therapy with 0.1% tacrolimus ointment (Protopic®) on intradermal skin test reactivity in atopic dogs. Vet Dermatol 2004;15:218-224.